Malaria drug-resistance reporting: keep the study period with the finding
Read the 2010 antimalarial-efficacy announcement through geography, study methods and time, without treating an old surveillance report as current care guidance.
Identify the period the evidence covers
The December 2010 WHO news item concerns monitoring antimalarial drug efficacy and early detection of resistance. WHO’s report overview identifies the underlying review period as 2000 to June 2010. That historical window is central to the meaning of the report.
A later retrieval does not extend the period its studies describe. Nor can an old regional finding automatically determine conditions at every destination today. Readers need the study period and location alongside any claim about resistance, just as they need a case definition and reporting cutoff alongside an outbreak count.
Ask what was measured
A report about drug efficacy needs to identify the method and the outcome it assessed. The response observed under a defined study, a laboratory observation and a wider programme indicator are different forms of evidence. A comparison is strongest when it keeps those forms separate before trying to combine them.
Time and follow-up matter too. Two reports can use different intervals or study conditions, so a numerical difference may not have a single explanation. The appropriate reading question is whether the methods support comparison. The existence of a medicine’s name in two studies is not sufficient to establish that their results measure the same thing.
Use historical evidence for the right purpose
The 2010 announcement shows why surveillance of efficacy was treated as a continuing task rather than a one-time declaration. Its historical value lies in how public-health programmes sought to detect changes and review evidence. It does not supply a current medicine-selection rule for a person or a travel destination.
Our comparison below is a guide to reading a resistance report, not an adaptation of a treatment guideline. It asks visitors to retain the place, period and measurement method. For an upcoming journey, the travel-reading guide explains why a historical research item and a current professional assessment have different roles.
Three boundaries of a resistance finding
| Boundary | What to retain | Avoid this shortcut |
|---|---|---|
| Time | The period studied and length of follow-up | Calling an older result a new assessment |
| Place and population | Where and in whom evidence was collected | Applying it identically everywhere |
| Method | The outcome and procedure used | Comparing unlike measures because a drug name matches |
Source snapshot · feed date 11 December 2010
WHO calls on malaria-endemic countries to strengthen monitoring of antimalarial drug efficacy
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000–2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Sources & Verification
World Health Organization (WHO). RSS content used with permission. Formatting adapted for Worldwide Outbreak.
- WHO calls on malaria-endemic countries to strengthen monitoring of antimalarial drug efficacy Verify original (opens in a new tab)
- WHO — antimalarial efficacy and resistance report, 2000–2010 Verify original (opens in a new tab)
Feed retrieved 24 Oct 2026, 14:09 UTC. Story date follows the dated WHO article address; the feed timestamp is 10 Jan 2020.
Pinterest
Reddit
